IBN started analyst coverage of Cardio Diagnostics Holdings, a precision medicine firm. The company integrates epigenetics and genetics with artificial intelligence to detect cardiovascular diseases. This move provides new financial visibility for the firm's AI-driven diagnostic approach. Practitioners should monitor how these specific biological markers improve clinical detection accuracy over traditional methods.